Press Releases

13 Dec 2018The Medicines Company Prices $150 Million of Convertible Notes12 Dec 2018The Medicines Company Announces Intention to Offer $150 Million of Convertible Notes11 Dec 2018The Medicines Company Appoints Mark Timney as Chief Executive Officer08 Nov 2018The Medicines Company Reports Third-Quarter 2018 Results01 Nov 2018The Medicines Company to Announce Third-Quarter 2018 Financial Results on November 801 Oct 2018The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Fourth Review of Unblinded Data01 Aug 2018The Medicines Company Reports Second-Quarter 2018 Results26 Jul 2018The Medicines Company to Announce Second-Quarter 2018 Financial Results on August 127 Jun 2018The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following [Third] Review of Unblinded Data26 Jun 2018New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes07 May 2018The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke30 Apr 2018The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions25 Apr 2018The Medicines Company Reports First-Quarter 2018 Results19 Apr 2018The Medicines Company to Announce First-Quarter 2018 Financial Results on April 2528 Mar 2018The Medicines Company Announces Chief Financial Officer Transition16 Mar 2018The Medicines Company to Participate in the Oppenheimer 28th Annual Healthcare Conference08 Mar 2018The Medicines Company to Participate in the Cowen 38th Annual Health Care Conference08 Mar 2018The Medicines Company Reaches Enrollment Target for ORION-10 Ahead of Schedule27 Feb 2018The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors21 Feb 2018The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results20 Feb 2018The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule14 Feb 2018The Medicines Company to Host Conference Call and Webcast Discussing Fourth-Quarter and Full-Year 2017 Financial Results08 Feb 2018The Medicines Company to Participate in the Leerink Partners 7th Annual Global Healthcare Conference25 Jan 2018Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule08 Jan 2018The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics03 Jan 2018The Medicines Company to Present at the 36th Annual J. P. Morgan Healthcare Conference

Contact Us

The Medicines Company
8 Sylvan Way
Parsippany, NJ 07054 USA
Tel 973 290 6000
Toll-free 800 388 1183
Global Medical Information

Human Resources
Verification of employment
Tel 973 290 6361
Fax 862 207 6361

Investors Relations

Krishna Gorti, MD
Tel 973 290 6122
krishna.gorti@themedco.com

Media Inquiries

Michael Blash
Tel 973 290 6100
michael.blash@themedco.com